Receiving a glioblastoma diagnosis often comes with a number: median survival of around 15 months. That number affects the patient and everyone in the room. It describes a large study population, not what will happen to one person. Once you understand what median survival measures and which biological and clinical factors affect individual outcomes in glioblastoma, you can make better decisions going forward.
What does median survival mean for glioblastoma?
Median survival is the midpoint in a study where half the patients died and half stayed alive. For glioblastoma patients who get the standard Stupp protocol - surgery plus concurrent chemoradiation and temozolomide chemotherapy, followed by more temozolomide - that midpoint is roughly 14 to 16 months in most large studies. Half the patients lived longer than that. It's not a ceiling.
Why this number does not define your prognosis
Population medians come from large, mixed groups across many hospitals, ages, and tumor types. A 36-year-old with a small frontal-lobe tumor, complete removal, and a methylated MGMT promoter looks nothing like the average trial patient. One number that mixes all ages, tumor types, and treatments describes almost no single person.
Most survival figures come from studies done between 2005 and 2015. A systematic review in Neuro-Oncology Practice (Brodbelt et al., 2020) found that two-year and three-year survival rates more than doubled after 2005 compared with earlier groups. Better surgical imaging, more TTFields use, and more molecular testing explain some of this increase. Patients diagnosed today often do better than those older numbers show.
You are not the average. You are a specific person with specific disease factors - and many of them are knowable from the start.
Which molecular factors shape your prognosis most?
Molecular testing of tumor tissue is the most important step. Two markers matter most in early decisions.
MGMT methylation
MGMT (O6-methylguanine-DNA methyltransferase) is a protein that fixes certain DNA damage in tumor cells, including damage from temozolomide chemotherapy. When methylation chemically silences the gene promoter that makes MGMT, the tumor can't repair damage as well, so temozolomide works better. Surgeons determine this methylation status from the tumor tissue they remove and report it in the final pathology.
Patients with a methylated MGMT promoter live longer than those without it. A study in the Journal of Clinical Medicine found that methylated patients had a median survival of 16.4 months versus 11.8 months for unmethylated patients on the same treatment. This difference matters for treatment planning - it affects how aggressively to use chemotherapy and whether to explore other options early.
MGMT methylation predicts both outcomes and response to temozolomide. Both matter for treatment planning.
IDH mutation status
Most glioblastomas are IDH-wildtype, meaning the isocitrate dehydrogenase gene has no mutation. A smaller subset - often in younger patients and in tumors that grew from a lower-grade tumor - carry an IDH mutation and act very differently. IDH-mutant tumors live longer and doctors treat them differently. Under the 2021 WHO classification, IDH-wildtype grade 4 astrocytoma is the formal name for what patients usually call glioblastoma. IDH-mutant tumors get a separate classification.
If your pathology report doesn't clearly show IDH status, or if only a small biopsy sample was taken, ask for more molecular testing. Our article on IDH-wildtype vs IDH-mutant glioblastoma: prognosis and treatment explains how the subtypes differ and what each means for treatment.
How age and functional status factor into survival
Younger patients do better in nearly every study. According to the NIH, younger age at diagnosis is one of the strongest predictors of longer survival. Younger patients more often tolerate the full Stupp protocol without dose cuts, complete all six temozolomide cycles, and qualify for clinical trials with newer drugs.
Functional status matters just as much. The Karnofsky Performance Status (KPS) scale rates patients from 0 to 100. A score of 70 or above - meaning a patient can care for themselves but can't do heavy work - predicts better outcomes and allows more treatment options. Lower KPS scores mean patients can't handle as much treatment.
KPS can improve. Managing symptoms early - controlling seizures, tapering steroids carefully, and keeping nutrition up - protects functional status during the critical weeks that determine which treatments you can have.
Does the extent of surgery change survival?
Yes. Evidence shows this across many studies. Complete removal - taking out as much tumor as possible without causing new nerve damage - leads to longer survival. A pooled analysis found that patients with complete removal had about half the risk of death at any time compared with those who had only partial removal.
Advanced surgical tools help. 5-ALA fluorescence-guided surgery uses an oral dye that makes tumor tissue glow pink-red under a certain light, so surgeons can see tumor edges in real time. Intraoperative MRI lets the team check for leftover tumor before closing. Not all hospitals use these tools, and the number of GBM resections the team does each year varies.
Our article on how glioblastoma extent of resection affects survival covers what to ask before and after surgery to make sure resection goals were met and confirmed on imaging.
What long-term survivors tend to have in common
Roughly 10 to 15% of glioblastoma patients live two or more years. They tend to share certain traits: younger age, MGMT-methylated tumors, complete resection, and high KPS scores at the start. According to the National Brain Tumor Society, the five-year survival rate for glioblastoma is about 5 to 7% across all patients - this includes older patients, those with hard-to-treat tumor types, and those at hospitals without specialized neuro-oncology programs.
Long-term survivors have specific traits. Some of these traits can change. Many were in clinical trials or got extra treatments like TTFields, which may improve survival when added to regular chemotherapy. But not all hospitals offer these options. Knowing which could help your situation is part of planning early.
Translating prognosis data into action
Use prognosis data to guide decisions, not as a fixed number. If MGMT-methylated patients respond better to temozolomide, get your molecular tests and make sure they're right. If complete resection improves outcomes, ask about the surgical plan and whether the center has the tools for it. If younger patients do better because they finish more treatment, manage symptoms from week one so side effects don't cut your doses.
If your hospital doesn't have a neuro-oncology specialist, or if your molecular tests are incomplete, get a second opinion before you start treatment. Patients and families abroad can get a remote second opinion through Art of Healing Cancer, where specialists review your pathology and imaging without travel.
Knowing your molecular markers helps you find clinical trials and precision treatment. Our article on when to seek a glioblastoma second opinion explains what triggers a second review, what it covers, and how to prepare your records.
If you want a clinical review of your prognostic factors, you can upload your MRI scans and pathology reports through the Glioblastoma Center patient journey form for a remote specialist review.
When to talk to your doctor
Ask about prognosis directly if you don't have MGMT methylation results or IDH status confirmed in writing. Ask your oncologist what your KPS score is and how it affects your treatment plan. If you're not sure whether complete resection happened, ask for the operative note and post-surgery MRI. If your hospital doesn't have a neuro-oncology specialist, ask for a referral or get a second opinion before starting treatment.
This article gives general information and is not medical advice. Always talk to your oncologist or care team about your specific situation.